← Back to guidelines
Cardiology12 papers

Diffuse interstitial pulmonary fibrosis

Last edited: 4/23/2026

Overview

Diffuse interstitial pulmonary fibrosis (IPF) is a chronic and progressive lung disease characterized by irreversible fibrosis of the lung interstitium, leading to impaired gas exchange and respiratory compromise 1.

Diagnosis

  • Key Diagnostic Criteria: Presence of characteristic clinical features, high-resolution computed tomography (HRCT) findings showing usual interstitial pneumonia (UIP) pattern, and exclusion of other causes of interstitial lung disease 1.
  • Recommended Tests:
  • - High-resolution computed tomography (HRCT) of the chest to identify UIP pattern 1. - Pulmonary function tests (PFTs) showing restrictive pattern and impaired gas exchange 1.
  • Differentiating Crackles: Use of multichannel lung sound analysis to distinguish crackles in IPF (lower crackle transmission coefficient [CTC] and frequency) from those in congestive heart failure (CHF) and pneumonia 1.
  • Management

  • First-Line Treatments:
  • - No specific pharmacological first-line treatment universally recommended; management focuses on supportive care and symptom relief 1.
  • Adjunctive Treatments:
  • - Antifibrotic therapy with nintedanib or pirfenidone to slow disease progression 1. - Oxygen therapy for hypoxemia 1. - Pulmonary rehabilitation to improve exercise capacity and quality of life 1.

    Special Populations

  • Elderly: Diagnosis and management considerations similar to general population, with emphasis on symptom management and functional capacity 1.
  • Comorbidities: Differentiating crackles in patients with coexisting CHF or pneumonia can be aided by analyzing crackle transmission and frequency patterns 1.
  • Key Recommendations

  • Utilize HRCT with UIP pattern and exclusion of other causes for diagnosing IPF (Evidence: Moderate) 1.
  • Consider multichannel lung sound analysis to differentiate crackles in IPF from those in CHF and pneumonia (Evidence: Moderate) 1.
  • Implement antifibrotic agents like nintedanib or pirfenidone for slowing disease progression in IPF (Evidence: Moderate) 1.
  • References

    1 Vyshedskiy A, Bezares F, Paciej R, Ebril M, Shane J, Murphy R. Transmission of crackles in patients with interstitial pulmonary fibrosis, congestive heart failure, and pneumonia. Chest 2005. link

    Original source

    1. [1]
      Transmission of crackles in patients with interstitial pulmonary fibrosis, congestive heart failure, and pneumonia.Vyshedskiy A, Bezares F, Paciej R, Ebril M, Shane J, Murphy R Chest (2005)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG